Serum DBI and biomarkers of neuroinflammation in Alzheimer's disease and delirium.
Alzheimer’s disease
Cytokines
Delirium
Diazepam binding inhibitor
Monocytes
Serum
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
06
05
2020
accepted:
16
07
2020
pubmed:
25
7
2020
medline:
15
5
2021
entrez:
25
7
2020
Statut:
ppublish
Résumé
Alzheimer's disease (AD) patients often express significant behavioral symptoms: for this reason, accessible related biomarkers could be very useful. Neuroinflammation is a key pathogenic process in both AD and delirium (DEL), a clinical condition with behavioral symptoms resembling those of AD. A total of n = 30 AD patients were recruited together with n = 30 DEL patients and n = 15 healthy controls (CTRL). Serum diazepam binding inhibitor (DBI), IL-17, IL-6, and TNF-α were assessed by ELISA. DBI serum levels were increased in AD patients with respect to CTRL (+ 81%), while DEL values were 70% higher than AD. IL-17 was increased in DEL with respect to CTRL (+ 146%), while AD showed dispersed values and failed to reach significant differences. On the other hand, IL-6 showed a more robust increase in DEL with respect to the other two groups (+ 185% and + 205% vs. CTRL and AD, respectively), and TNF-α failed to show any change. DBI may be a very promising candidate for AD, perhaps marking psychomotor DEL-like symptoms, in view of developing future helping tool for practicing physicians. Furthermore, DBI rise in DEL offers novel cues for a better comprehension of the pathogenesis of this potentially fatal condition.
Sections du résumé
BACKGROUND
BACKGROUND
Alzheimer's disease (AD) patients often express significant behavioral symptoms: for this reason, accessible related biomarkers could be very useful. Neuroinflammation is a key pathogenic process in both AD and delirium (DEL), a clinical condition with behavioral symptoms resembling those of AD.
METHODS
METHODS
A total of n = 30 AD patients were recruited together with n = 30 DEL patients and n = 15 healthy controls (CTRL). Serum diazepam binding inhibitor (DBI), IL-17, IL-6, and TNF-α were assessed by ELISA.
RESULTS
RESULTS
DBI serum levels were increased in AD patients with respect to CTRL (+ 81%), while DEL values were 70% higher than AD. IL-17 was increased in DEL with respect to CTRL (+ 146%), while AD showed dispersed values and failed to reach significant differences. On the other hand, IL-6 showed a more robust increase in DEL with respect to the other two groups (+ 185% and + 205% vs. CTRL and AD, respectively), and TNF-α failed to show any change.
CONCLUSIONS
CONCLUSIONS
DBI may be a very promising candidate for AD, perhaps marking psychomotor DEL-like symptoms, in view of developing future helping tool for practicing physicians. Furthermore, DBI rise in DEL offers novel cues for a better comprehension of the pathogenesis of this potentially fatal condition.
Identifiants
pubmed: 32705487
doi: 10.1007/s10072-020-04608-x
pii: 10.1007/s10072-020-04608-x
pmc: PMC7870594
doi:
Substances chimiques
Biomarkers
0
Diazepam Binding Inhibitor
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1003-1007Références
Cloak N, Al Khalili Y (2020) Behavioral and psychological symptoms in dementia (BPSD). StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2020 Jan-2019 Dec 8
Spalletta G, Musicco M, Padovani A, Rozzini L, Perri R, Fadda L, Canonico V, Trequattrini A, Pettenati C, Caltagirone C, Palmer K (2010) Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease. Am J Geriatr Psychiatry 18:1026–1035. https://doi.org/10.1097/JGP.0b013e3181d6b68d
doi: 10.1097/JGP.0b013e3181d6b68d
pubmed: 20808086
Conti E, Grana D, Stefanoni G, Corsini A, Botta M, Magni P, Aliprandi A, Lunetta C, Appollonio I, Ferrarese C, Tremolizzo L (2019) Irisin and BDNF serum levels and behavioral disturbances in Alzheimer’s disease. Neurol Sci 40:1145–1150. https://doi.org/10.1007/s10072-019-03781-y
doi: 10.1007/s10072-019-03781-y
pubmed: 30810826
Lee Y, Lee BH, Yip W, Chou P, Yip BS (2020) Neurofilament proteins as prognostic biomarkers in neurological disorders. Curr Pharm Des 25:4560–4569. https://doi.org/10.2174/1381612825666191210154535
doi: 10.2174/1381612825666191210154535
pubmed: 31820696
O’Callaghan JP, Miller DB (2019) Neuroinflammation disorders exacerbated by environmental stressors. Metabolism 100S:153951. https://doi.org/10.1016/j.metabol.2019.153951
doi: 10.1016/j.metabol.2019.153951
pubmed: 31610852
Fong TG, Davis D, Growdon ME, Albuquerque A, Inouye SK (2015) The interface between delirium and dementia in elderly adults. Lancet Neurol 14:823–832. https://doi.org/10.1016/S1474-4422(15)00101-5
doi: 10.1016/S1474-4422(15)00101-5
pubmed: 26139023
pmcid: 4535349
Maldonado JR (2018) Delirium pathophysiology: an updated hypothesis of the etiology of acute brain failure. Int J Geriatr Psychiatry 33:1428–1457. https://doi.org/10.1002/gps.4823
doi: 10.1002/gps.4823
pubmed: 29278283
McNeil JB, Hughes CG, Girard T, Ware LB, Ely EW, Chandrasekhar R, Han JH (2019) Plasma biomarkers of inflammation, coagulation, and brain injury as predictors of delirium duration in older hospitalized patients. PLoS One 14:e0226412. https://doi.org/10.1371/journal.pone.0226412
doi: 10.1371/journal.pone.0226412
pubmed: 31856187
pmcid: 6922408
Hall RJ, Watne LO, Cunningham E, Zetterberg H, Shenkin SD, Wyller TB, MacLullich AMJ (2018) CSF biomarkers in delirium: a systematic review. Int J Geriatr Psychiatry 33:1479–1500. https://doi.org/10.1002/gps.4720
doi: 10.1002/gps.4720
pubmed: 28585290
Khan BA, Perkins AJ, Prasad NK, Shekhar A, Campbell NL, Gao S, Wang S, Khan SH, HL MERT 3rd, Boustani MA (2020) Biomarkers of delirium duration and delirium severity in the ICU. Crit Care Med 48:353–361. https://doi.org/10.1097/CCM.0000000000004139
doi: 10.1097/CCM.0000000000004139
pubmed: 31770149
Guidotti A (1991) Role of DBI in brain and its posttranslational processing products in normal and abnormal behavior. Neuropharmacology 30:1425–1433. https://doi.org/10.1016/s0028-3908(11)80012-2
doi: 10.1016/s0028-3908(11)80012-2
pubmed: 1664069
Betlazar C, Middleton RJ, Banati R, Liu GJ (2020) The translocator protein (TSPO) in mitochondrial bioenergetics and immune processes. Cells 9:E512. https://doi.org/10.3390/cells9020512
doi: 10.3390/cells9020512
pubmed: 32102369
Sacerdote P, Panerai AE, Frattola L, Ferrarese C (1999) Benzodiazepine-induced chemotaxis is impaired in monocytes from patients with generalized anxiety disorder. Psychoneuroendocrinology 24:243–249. https://doi.org/10.1016/s0306-4530(98)00079-1
doi: 10.1016/s0306-4530(98)00079-1
pubmed: 10101731
Tonon MC, Vaudry H, Chuquet J, Guillebaud F, Fan J, Masmoudi-Kouki O, Vaudry D, Lanfray D, Morin F, Prevot V, Papadopoulos V, Troadec JD, Leprince J (2019) Endozepines and their receptors: structure, functions and pathophysiological significance. Pharmacol Ther 107386:107386. https://doi.org/10.1016/j.pharmthera.2019.06.008
doi: 10.1016/j.pharmthera.2019.06.008
Thoeringer CK, Binder EB, Salyakina D, Erhardt A, Ising M, Unschuld PG, Kern N, Lucae S, Brueckl TM, Mueller MB, Fuchs B, Puetz B, Lieb R, Uhr M, Holsboer F, Mueller-Myhsok B, Keck ME (2007) Association of a Met88Val diazepam binding inhibitor (DBI) gene polymorphism and anxiety disorders with panic attacks. J Psychiatr Res 41:579–584. https://doi.org/10.1016/j.jpsychires.2006.06.001
doi: 10.1016/j.jpsychires.2006.06.001
pubmed: 16904689
Moro V, Valbusa V, Corsi N, Bonazzi A, Condoleo MT, Broggio E, Gambina G (2020) Comprehension of written texts for the assessment of clinical competence and decision making in people with mild to moderate Alzheimer disease. Neurol Sci in press 41:1225–1231. https://doi.org/10.1007/s10072-019-04228-0
doi: 10.1007/s10072-019-04228-0
pubmed: 31901122
Morandi A, Thompson JL, Bellelli G, Lucchi E, Turco R, Gentile S, Trabucchi M, MacLullich A, Meagher D, Ely EW, Pandharipande P, Smith H (2019) Delirium in patients with dementia and in children: overlap of symptoms profile and possible role for future diagnosis. Eur J Intern Med 65:44–50. https://doi.org/10.1016/j.ejim.2019.04.023
doi: 10.1016/j.ejim.2019.04.023
pubmed: 31151748
Ransohoff RM, Brown MA (2012) Innate immunity in the central nervous system. J Clin Invest 122:1164–1171. https://doi.org/10.1172/JCI58644
doi: 10.1172/JCI58644
pubmed: 22466658
pmcid: 3314450
Gate D, Rezai-Zadeh K, Jodry D, Rentsendorj A, Town T (2010) Macrophages in Alzheimer’s disease: the blood-borne identity. J Neural Transm (Vienna) 117:961–970. https://doi.org/10.1007/s00702-010-0422-7
doi: 10.1007/s00702-010-0422-7
Lee WJ, Liao YC, Wang YF, Lin IF, Wang SJ, Fuh JL (2018) Plasma MCP-1 and cognitive decline in patients with Alzheimer’s disease and mild cognitive impairment: a two-year follow-up study. Sci Rep 8:1280. https://doi.org/10.1038/s41598-018-19807-y
doi: 10.1038/s41598-018-19807-y
pubmed: 29352259
pmcid: 5775300
Ferrarese C, Appollonio I, Bianchi G, Frigo M, Marzorati C, Pecora N, Perego M, Pierpaoli C, Frattola L (1993) Benzodiazepine receptors and diazepam binding inhibitor: a possible link between stress, anxiety and the immune system. Psychoneuroendocrinology 18:3–22. https://doi.org/10.1016/0306-4530(93)90051-l
doi: 10.1016/0306-4530(93)90051-l
pubmed: 8386386
Pluchino N, Russo M, Santoro AN, Litta P, Cela V, Genazzani AR (2013) Steroid hormones and BDNF. Neuroscience 239:271–279. https://doi.org/10.1016/j.neuroscience.2013.01.025
doi: 10.1016/j.neuroscience.2013.01.025
pubmed: 23380505
Schverer M, Lanfumey L, Baulieu EE, Froger N, Villey I (2018) Neurosteroids: non-genomic pathways in neuroplasticity and involvement in neurological diseases. Pharmacol Ther 191:190–206. https://doi.org/10.1016/j.pharmthera.2018.06.011
doi: 10.1016/j.pharmthera.2018.06.011
pubmed: 29953900
Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M (2010) Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 9:971–988. https://doi.org/10.1038/nrd3295
doi: 10.1038/nrd3295
pubmed: 21119734
Solas M, Puerta E, Ramirez MJ (2015) Treatment options in Alzheimer’s disease: the GABA story. Curr Pharm Des 21:4960–4971. https://doi.org/10.2174/1381612821666150914121149
doi: 10.2174/1381612821666150914121149
pubmed: 26365140
Costa E, Davis JM, Dong E, Grayson DR, Guidotti A, Tremolizzo L, Veldic M (2004) A GABAergic cortical deficit dominates schizophrenia pathophysiology. Crit Rev Neurobiol 16:1–23. https://doi.org/10.1615/critrevneurobiol.v16.i12.10
doi: 10.1615/critrevneurobiol.v16.i12.10
pubmed: 15581395
Rudolph JL, Ramlawi B, Kuchel GA, McElhaney JE, Xie D, Sellke FW, Khabbaz K, Levkoff SE, Marcantonio ER (2008) Chemokines are associated with delirium after cardiac surgery. J Gerontol A Biol Sci Med Sci 63:184–189. https://doi.org/10.1093/gerona/63.2.184
doi: 10.1093/gerona/63.2.184
pubmed: 18314455
pmcid: 2735245
Erikson K, Ala-Kokko TI, Koskenkari J, Liisanantti JH, Kamakura R, Herzig KH, Syrjälä H (2019) Elevated serum S-100β in patients with septic shock is associated with delirium. Acta Anaesthesiol Scand 63:69–73. https://doi.org/10.1111/aas.13228
doi: 10.1111/aas.13228
pubmed: 30079511
Chen Y, Lu S, Wu Y, Shen Y, Zhao H, Ding S, Feng X, Sun L, Tao X, Li J, Ma R, Liu W, Wu F, Feng Y (2019) Change in serum level of interleukin 6 and delirium after coronary artery bypass graft. Am J Crit Care 28:462–470. https://doi.org/10.4037/ajcc2019976
doi: 10.4037/ajcc2019976
pubmed: 31676521
Costa E, Guidotti A (1991) Diazepam binding inhibitor (DBI): a peptide with multiple biological actions. Life Sci 49:325–344. https://doi.org/10.1016/0024-3205(91)90440-m
doi: 10.1016/0024-3205(91)90440-m
pubmed: 1649940